Bartlett, J A <br/><br/>
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.  [electronic resource] 

 -  Annals of internal medicine  Aug 1996 
 - 161-72 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0003-4819 
<br/><br/><label>Standard No.: </label>10.7326/0003-4819-125-3-199608010-00001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--adverse effects<br/>Biopterins--analogs & derivatives<br/>CD4 Lymphocyte Count<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>HIV--genetics<br/>HIV Core Protein p24--blood<br/>HIV Infections--blood<br/>Humans<br/>Lamivudine<br/>Male<br/>Neopterin<br/>Polymerase Chain Reaction<br/>RNA, Viral--blood<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome<br/>Zalcitabine--adverse effects<br/>Zidovudine--adverse effects<br/>beta 2-Microglobulin--metabolism